Vaborbactam

Vaborbactam
Clinical data
ATC code	None;
Identifiers
	IUPAC name {(3R,6S)-2-Hydroxy-3-[2-(thiophen-2-yl)acetamido]-; 1,2-oxaborinan-6-yl}acetic acid;
CAS Number	1360457-46-0;
PubChem CID	56649692;
DrugBank	DB12107;
ChemSpider	35035409;
UNII	1C75676F8V;
KEGG	D10998;
CompTox Dashboard (EPA)	DTXSID901027690 ;
ECHA InfoCard	100.235.136
Chemical and physical data
Formula	C12H16BNO5S
Molar mass	297.13 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O;
	InChI InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1; Key:IOOWNWLVCOUUEX-WPRPVWTQSA-N;

Vaborbactam (INN)^[1] is a non-β-lactam β-lactamase inhibitor discovered by Rempex Pharmaceuticals, a subsidiary of The Medicines Company. While not effective as an antibiotic by itself, it restores potency to existing antibiotics by inhibiting the β-lactamase enzymes that would otherwise degrade them. When combined with an appropriate antibiotic it can be used for the treatment of gram-negative bacterial infections.^[2]

In the United States, the combination drug meropenem/vaborbactam (Vabomere) is approved by the Food and Drug Administration for complicated urinary tract infections and pyelonephritis.^[3] The combination was approved for medical use in Canada in December 2024.^[4]

^ World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information. 30 (1). hdl:10665/331046.
^ Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, et al. (May 2015). "Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases". Journal of Medicinal Chemistry. 58 (9): 3682–92. doi:10.1021/acs.jmedchem.5b00127. PMID 25782055.{{cite journal}}: CS1 maint: overridden setting (link)
^ "FDA approves new antibacterial drug" (Press release). U.S. Food and Drug Administration. 29 August 2017. Archived from the original on 11 December 2019.
^ "Register of Innovative Drugs". Health Canada. 13 January 2025. Retrieved 15 January 2025.

[INN-1] World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information. 30 (1). hdl:10665/331046.

[Hecker-2] Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, et al. (May 2015). "Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases". Journal of Medicinal Chemistry. 58 (9): 3682–92. doi:10.1021/acs.jmedchem.5b00127. PMID 25782055.{{cite journal}}: CS1 maint: overridden setting (link)

[3] "FDA approves new antibacterial drug" (Press release). U.S. Food and Drug Administration. 29 August 2017. Archived from the original on 11 December 2019.

[4] "Register of Innovative Drugs". Health Canada. 13 January 2025. Retrieved 15 January 2025.

[1]

[2]

[3]

[4]